American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non–small-cell lung cancer and good performance status

ASCO 2016 – Lung Cancer

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C

ASCO 2016 – Lung Cancer

Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC)

ASCO 2016 – Lung Cancer

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–positive NSCLC

ASCO 2016 – Lung Cancer

Response to tyrosine kinase inhibitors in advanced non–small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation

ASCO 2016 – Lung Cancer

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer

ASCO 2016 – Lung Cancer

Treating Gastric Cancer by Targeting Notch and wnt-Beta-Catenin Cancer Stem-Cell Pathways

ASCO 2016 – GI

An in vitro study to determine whether inactivation of the Notch and wnt-beta-catenin pathways is crucial for cancer stem-cell development and if such a therapeutic approach with a γ-secretase inhibitor would be effective in treating patients with gastric cancer. Read More ›

BBI608/FOLFIRI ± Bevacizumab in Advanced Colorectal Cancer

ASCO 2016 – GI

NEO-102, an Anti-MUC5AC Monoclonal Antibody, in Chemotherapy-Refractory Metastatic Colorectal Cancer

ASCO 2016 – GI

Initial results from a phase 2 open-label study of NEO-102, a novel chimeric monoclonal antibody targeting a variant of MUC5AC, in patients with chemotherapy-refractory metastatic colorectal cancer. Read More ›

American Society of Clinical Oncology (ASCO)

Page 21 of 31